Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Update

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 352,300 shares, a growth of 20.8% from the February 28th total of 291,600 shares. Based on an average daily volume of 141,900 shares, the short-interest ratio is currently 2.5 days. Approximately 0.6% of the company's shares are short sold.

Nautilus Biotechnology Price Performance

NAUT stock traded up $0.11 during trading hours on Monday, reaching $0.80. 236,209 shares of the stock were exchanged, compared to its average volume of 102,055. The company has a market cap of $101.44 million, a price-to-earnings ratio of -1.44 and a beta of 1.39. The firm's 50-day moving average is $1.32 and its 200-day moving average is $1.97. Nautilus Biotechnology has a 12 month low of $0.63 and a 12 month high of $3.09.

Insider Buying and Selling

In other news, CEO Sujal M. Patel acquired 53,300 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was purchased at an average cost of $0.99 per share, with a total value of $52,767.00. Following the acquisition, the chief executive officer now owns 10,117,788 shares of the company's stock, valued at $10,016,610.12. This trade represents a 0.53 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 40.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Nautilus Biotechnology

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in shares of Nautilus Biotechnology by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,142,542 shares of the company's stock worth $1,920,000 after purchasing an additional 7,000 shares during the last quarter. Palumbo Wealth Management LLC lifted its stake in Nautilus Biotechnology by 45.4% in the 4th quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company's stock valued at $48,000 after purchasing an additional 8,888 shares during the last quarter. SG Americas Securities LLC increased its position in Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company's stock worth $46,000 after buying an additional 9,904 shares during the last quarter. Bank of America Corp DE raised its stake in Nautilus Biotechnology by 37.1% in the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company's stock valued at $83,000 after buying an additional 13,363 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Nautilus Biotechnology in the fourth quarter valued at about $28,000. Institutional investors own 50.71% of the company's stock.

Analysts Set New Price Targets

Separately, Guggenheim set a $2.50 target price on shares of Nautilus Biotechnology in a report on Friday, February 28th.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.